Status:
COMPLETED
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Lead Sponsor:
Angelini Farmacéutica
Collaborating Sponsors:
Apices Soluciones S.L.
Conditions:
Breakthrough Pain
Eligibility:
All Genders
18+ years
Brief Summary
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment....
Eligibility Criteria
Inclusion
- Patients \> 18 years
- Patients with histologically confirmed neoplasia
- Patients attended in medical oncology consultations
- Life expectancy \> 3 months
- Patients with baseline controlled cancer pain with opioids who are diagnosed of breakthrough cancer pain by Davies algorithm
- Written informed consent
Exclusion
- Untreated patients with opioids for baseline pain
- Patients who are not opioid tolerant
- Serious psychiatric disorder or any disease or condition that prevents the collection of data
- Patients with evidence of opioid addiction or history of drug or alcohol abuse
Key Trial Info
Start Date :
December 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 14 2020
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT03435120
Start Date
December 21 2017
End Date
February 14 2020
Last Update
March 2 2020
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, Spain, 15706
2
Hospital Principe de Asturias
Alcalá de Henares, Madrid, Spain
3
Hospital Universitari Son Espases
Palma de Mallorca, Palma, Spain
4
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain, 33011